CagriSema
Stories
-
Novo Nordisk registers Phase 3 trial of CagriSema in hypertension and obesity
The study, titled Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) in Participants With Hypertension and Obesity, plans to enroll 1408 participants and is expected to start on November 11, 2026. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo in a randomized, quadruple-masked design.